Glucose-dependent insulinotropic polypeptide (GIP)
Deutsches Diabetes-Zentrum e.V. · German Center for Diabetes Research · +27 more institutions
Abstract
BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and…
Citation impact
- FWCI
- 53.59
- Percentile
- 100%
- References
- 1,142
Authors
39- TDTimo D. MüllerCorresponding
Deutsches Diabetes-Zentrum e.V., German Center for Diabetes Research, Heinrich Heine University Düsseldorf, Ludwig-Maximilians-Universität München
- AEAlice E. Adriaenssens
University College London
- BABo Ahrén
Lund University
- MBMatthias Blüher
University Hospital Leipzig
- ALAndreas L. Birkenfeld
Deutsches Diabetes-Zentrum e.V., German Center for Diabetes Research, Heinrich Heine University Düsseldorf
Topics & keywords
- Endocrinology
- Internal medicine
- Gastric inhibitory polypeptide
- Medicine
- Chemistry
- Insulin
- Glucagon
- Good health and well-being
Funding
- ELEli Lilly and Company
- PPfizer
- INInvest Northern Ireland
- DUDiabetes UK
- ECEuropean CommissionAwards: 101044445, SFB1123
- EFEuropean Foundation for the Study of Diabetes
- DFDeutsche ForschungsgemeinschaftAwards: SFB1123, TRR152, GRK 2816/1, DFG TRR296, TRR296
- NNNovo Nordisk
- NNNovo Nordisk FondenAward: NNF21OC0070347
- CICanadian Institutes of Health Research
- EREuropean Research Council
- NHNational Health and Medical Research CouncilAward: 2026300